Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia

M. Kibata, M. Ishida, K. Asano, H. Uehara, K. Saito, T. Fuchimoto, K. Ugaki, H. Murakami, K. Matoba, Y. Kotakemori, K. Shirai, H. Yoshioka, M. Nanba, M. Yasuda, M. Ishizaki, N. Kitagawa, K. Ikejiriu, R. Inohara, B. J. Lee, S. SainoJ. Sakado, H. Matuzaka, K. Numata, M. Mandai, K. Miyake, K. Nakamura

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


The effects of niceritrol, a nicotinic acid derivative, on the levels of HDLcholesterol (HDL-Ch) and a mixture of VLDL- and LDL-Ch (VLDL- + LDLCh) were studied in hyperlipidemic patients. Serum total cholesterol (sTC) and serum triglyceride (sTG) were significantly reduced during niceritrol administration. Lipoprotein electrophoresis showed that niceritrol increased the a :p ratio. HDL-Ch showed a significant increase of 12.5% by the 16th week of therapy. This increase was more marked in patients with lower pre-treatment HDL-Ch levels and significant in patients whose pretreatment sTG levels were in excess of 200 mg/dl. Females displayed higher pre-treatment HDL-Ch levels (38.5 mg/dl) than males (30.6 mg/dl). However, niceritrol increased HDL-Ch significantly in both groups. At 16 weeks, the VLDL- + LDL-Ch level showed a significant decrease of 9.2%; the HDLCh:VLDL + LDL-Ch and HDL-Ch:sTC ratios were significantly increased throughout niceritrol administration. Niceritrol is thought to be effective in preventing the development and progression of atherosclerosis because it raises the level of anti-atherogenic HDL-Ch and lowers the level of atherogenic VLDL- + LDL-Ch.

Original languageEnglish
Pages (from-to)333-342
Number of pages10
Issue number3
Publication statusPublished - 1980


  • Gas-liquid chromatography
  • HDL-cholesterol
  • Hyperlipidemia
  • LDLcholesterol
  • Niceritrol
  • Nicotinic acid

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia'. Together they form a unique fingerprint.

Cite this